Legend Biotech (LEGN) Common Equity (2019 - 2025)
Legend Biotech's (LEGN) quarterly Common Equity came in at $1.0 billion in Q4 2025, down 3.7% YoY from $1.0 billion in Q4 2024, and down 0.91% on a QoQ basis from $1.0 billion in Q3 2025.
Legend Biotech (LEGN) Common Equity (2019 - 2025) Analysis & Trends
Legend Biotech (LEGN) has 7 years of Common Equity data on file, last reported at $1.0 billion in Q4 2025.
- Quarterly Common Equity fell 3.7% year-over-year to $1.0 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 billion (down 3.7% YoY) and the FY2025 annual result came in at $1.0 billion, down 3.7% from the prior year.
- Common Equity declined to $1.0 billion in Q4 2025, from $1.0 billion in the prior quarter.
- In the past five years, Common Equity ranged from a high of $1.4 billion in Q2 2023 to a low of $206451.0 in Q1 2021.
- A 5-year average of $889.7 million and a median of $1.0 billion in 2025 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity soared 358900.44% — and 2024, when it dropped 17.63%.
- Tracing LEGN's Common Equity over 5 years: stood at $765.9 million in 2021, then dropped by 2.82% to $744.3 million in 2022, then soared by 68.12% to $1.3 billion in 2023, then slipped by 16.84% to $1.0 billion in 2024, then declined by 3.7% to $1.0 billion in 2025.
- The last three Common Equity figures came in at $1.0 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.0 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.00 Bn |
| Sep 30, 2025 | 1.01 Bn |
| Jun 30, 2025 | 1.04 Bn |
| Mar 31, 2025 | 1.02 Bn |
| Dec 31, 2024 | 1.04 Bn |
| Sep 30, 2024 | 1.12 Bn |
| Jun 30, 2024 | 1.16 Bn |
| Mar 31, 2024 | 1.16 Bn |
| Dec 31, 2023 | 1.25 Bn |
| Sep 30, 2023 | 1.34 Bn |
| Jun 30, 2023 | 1.41 Bn |
| Mar 31, 2023 | 653.16 Mn |
| Dec 31, 2022 | 744.31 Mn |
| Mar 31, 2022 | 741.16 Mn |
| Dec 31, 2021 | 765.94 Mn |
| Sep 30, 2021 | 225.87 Mn |
| Jun 30, 2021 | 339.92 Mn |
| Mar 31, 2021 | 206,451.00 |
| Dec 31, 2020 | 597.77 Mn |
| Sep 30, 2020 | 334,900.00 |